Aditxt Inc (ADTX) Actualités

Form 8-K/A - Current report: [Amend]

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Court’s...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 PR Newswire SAN DIEGO, Nov. 14...

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented at IDWeek...

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Shelf utilization inclusive of the ELOC and ATM, will be suspended during the stale period beginning Monday, November 11, 2024 Aditxt, Inc...

Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations...

Appili Therapeutics Announces Results of Special Meeting of Shareholders

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova...

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations...

Evofem Secures Investor Support for Proposed Merger through Voting Agreements

Evofem Secures Investor Support for Proposed Merger through Voting Agreements PR Newswire SAN DIEGO, Nov. 6...

Form 8-K - Current report

Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations...